WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
ImmunoTek Bio Centers | April 27, 2022
Donating plasma is now easier, thanks to a smart new tool allowing technicians to see the map of veins inside a plasma donor's arm. ImmunoTek Bio Centers proudly announces its two divisions – ImmunoTek Plasma and Freedom Plasma – are the first blood plasma collection centers to use this groundbreaking technology. The VeinViewer®, developed by Christie Medical Holdings, has had great success in hospitals and medical clinics, and recently in pilot programs with ImmunoTek. Using...
Absci | October 23, 2021
Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years.
“Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...
Quantum Genomics | December 06, 2021
Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey.
A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...
Cell and Gene Therapy, Industry Outlook
Globenewswire | May 10, 2023
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to detect and treat disease, announced that the U.S. Food and Drug Administration has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, a member of the Roche Group, for a T-cell receptor (TCR) based T-Cell Therapy. This is the first TCR-based therapeutic product candidate t...
Industrial Impact, Medical
Cell and Gene Therapy
AI, Industrial Impact
Cell and Gene Therapy, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE